Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Last updated: October 19, 2024
Sponsor: Hunan Province Tumor Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

Alectinib 150 MG

Crizotinib 250 MG

Osimertinib

Clinical Study ID

NCT04322890
20200311
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Understand the requirements and contents of the clinical trial, and provide a signedand dated informed consent form.

  2. Age ≥ 18 years.

  3. Histologically or cytologically confirmed, Stage IV NSCLC.

  4. Oncogenic mutations confirmed by an accredited local laboratory, including EGFR,ALK, ROS1 etc.

  5. ECOG 0-1.

  6. Predicted survival ≥ 12 weeks.

  7. Adequate bone marrow hematopoiesis and organ function

  8. Presence of measurable lesions according to RECIST 1.1.

Exclusion

Exclusion Criteria:

The patient did not match from the Inclusion Criteria.

Study Design

Total Participants: 6000
Treatment Group(s): 5
Primary Treatment: Alectinib 150 MG
Phase: 2
Study Start date:
April 16, 2020
Estimated Completion Date:
December 24, 2027

Study Description

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Our study was set up with several group with EGFR mutant, ALK fusion, ROS1 fusion, RET fusion, BRAF mutation, NRG1 fusion, MET alteration, KRAS mutation, etc.

Connect with a study center

  • Yongchang Zhang

    Changsha, Hunan 410013
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.